Logo
About usInnovation CMChallengesEuropa2iEntrepreneurshipR&D&I SearchAgentsEventsReports
en
BACTERIOPHAGES SUITABLE FOR TREATING A BACTERIAL INFECTION CAUSED BY KLEBSIELLA PNEUMONIAECM Patents

Índice de la ficha

Updated at
24/07/2026
Numero publicacion
EP.4265264.A1
Fecha publicacion
25/10/2023
Numero solicitud
EP20220382362
Fecha presentacion
19/04/2022

En detalle

Resumen

The present invention refers to a bacteriophage deposited at the German Collection of Microorganisms and Cell Cultures GmbH (Leibniz Institute) (DSMZ)with deposit number DSM34222, and to a bacteriophage characterized by comprising a nucleic acid consisting of SEQ ID NO: 1 In a preferred embodiment, the bacteriophages are used for treating bacterial infections caused by Klebsiella pneumoniae.

Reivindicaciones

1. Bacteriophage, characterized by their specificity for Klebsiella pneumoniae strains, selected from a bacteriophage deposited at the German Collection of Microorganisms and Cell Cultures GmbH (DSMZ) with deposit number DSM34222; a bacteriophage characterized by comprising a nucleic acid consisting of SEQ ID NO: 1; or a bacteriophage comprising a nucleic acid having at least 95% of identity with the nucleic acid of the bacteriophage DSM 34222 or the SEQ ID NO: 1. 2. Bacteriophage, according to claim 1, deposited at the German Collection of Microorganisms and Cell Cultures GmbH (DSMZ) with deposit number DSM34222. 3. Bacteriophage, according to any of the claims 1 or 2, for use as a medicament. 4. Bacteriophage for use, according to claim 3, in the prevention or treatment of a bacterial infection caused by Klebsiella pneumoniae. 5. Bacteriophage for use, according to any of the claims 3 or 4, in combination with an antibiotic, preferably selected from: polymyxin B and/or colistin. 6. Pharmaceutical composition comprising a bacteriophage according to claims 1 or 2 and, optionally, pharmaceutically acceptable excipients or carriers. 7. Pharmaceutical composition, according to claim 6, further comprising an antibiotic preferably selected from: polymyxin B and/or colistin. 8. Pharmaceutical composition according to claims 6 or 7 for use as a medicament. 9. Pharmaceutical composition for use, according to claim 8, in the prevention or treatment of a bacterial infection caused by Klebsiella pneumoniae. 10. A method of detecting the presence of Klebsiella pneumoniaein an in vitro sample, comprising contacting said sample with a bacteriophage according to claims1 or 2, and determining whether said bacteriophages kill bacteria in said sample.

Etiquetas

Inventores
García Quintanilla Meritxell de JesúsEsteban Moreno JaimeGadea Gironés IgnacioFernández Roblas RicardoAguilera Correa John JairoSenhaji Kacha Abrar
Solicitantes
Fundacion Instituto de Investigacion Sanitaria Fundacion Jimenez DiazUniversidad Complutense de Madrid
Clasificacion ipc
A61K 35/ 76 A IA61K 38/ 16 A IA61P 31/ 04 A IC12N 7/ 00 A I
Logo

Innovation CM
Challenges
Europa2i
Entrepreneurship
R&D&I Search
Agents
Events
Reports
About us
Contact
Give us your opinion
Cookies
Legal notice
Privacy

© Copyright Espacio Madrileño de Investigación e Innovación 2026